IDH1 and acute myeloid leukemia: In our cohort of AML patients undergoing either alloHCT or chemo-consolidation in CR1, 18.4% (n = 596) had an IDHmut with a median variant allele frequency (VAF) of 39% (IQR 26.2–43.2) for IDH1 and 38.1% (IQR 31.7–43.6) for IDH2. A total of 7.8% (n = 253) had mutated IDH1, 10.9% (n = 353) had mutated IDH2, while 0.3% (n = 10) had mutations in both IDH1 and IDH2. The most common IDH1 mutational subgroups were R132C (36%) and R132H (47%), while R132G, R132L and R132S were present in only few patients (7%, 5% and 6%, respectively).